U.S. Food and Drug Administration approves new drug for menopausal contraception

a new menopausal pill, recently approved by the U.SFood and Drug Administration, will be available in the U.Sfrom JulyThe new drug, called Lybrel,2
8 days per pack, providing a steady low-dose hormone to prevent menstruation, AFP reportedDoctors have long allowed women to start taking drugs on22days of their cycle to skip menstrual,rather than waiting a week for hormone levels to recover"
for women who choose birth control pills and want to stop,Lybrel is the right choice," said Ginger Constantine, deputy director of women'shealthat Wyeth Pharmaceuticals, which developed Lybrel "
but women who previously wanted to stop using contraception had other approved options A drug that reduces the number of menstruations to four times a year has been on the market for some time Women who want to avoid menstruation altogether can also inject hormones every three months the Food and Drug Administration cautions 41 percent of women who use Lybrel in clinical studies have an irregular bleeding , although the phenomenon decreases over time It recommends that professionals and patients in the medical health care when considering the use of Lybrel, make a trade-off and choice between the convenience of not having normal menstruation and the inconvenience of irregular bleeding or staining The Food and Drug Administration also cautions that a normal menstruation can also make it difficult for women to know if they are pregnant (
reprinted from "Xinhuanet")